What have we learned from trials on antiangiogenic agents in glioblastoma?

Expert Review of Neurotherapeutics

Volumn 14, Issue 1, 2014, Pages 1-3

  Soffietti, Riccardo ^a   Trevisan, Elisa ^a   Rudà, Roberta ^a  

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CILENGITIDE; ERLOTINIB; ETOPOSIDE; IRINOTECAN; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; STEROID; TEMOZOLOMIDE; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ADD ON THERAPY; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; COGNITIVE DEFECT; DRUG APPROVAL; DRUG EFFICACY; DRUG TARGETING; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; OFF LABEL DRUG USE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROMOTER REGION; QUALITY OF LIFE; REVIEW; RISK; TREATMENT OUTCOME; TUMOR CELL; TUMOR RECURRENCE; UNITED STATES;

ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOBLASTOMA; HUMANS;

EID: 84893063922     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.873277     Document Type: Review

References (11)

1. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma - Are we there yet? Neuro Oncol 2013;15(1):4-27
2. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307(5706):58-62
3. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-40
4. Taal W, Oosterkamp HM, Walenkamp AME, et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. J Clin Oncol 2013;31(15S):2001
5. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013;31(26): 3212-18
6. Chinot O, Cloughesy T, Henriksson R, et al. Efficacy and safety of bevacizumab (Bv) plus standard combination temozolomide (T) and radioterapy (RT) in newly diagnosed glioblastoma: Fainal results froma AVAglio. Eur J Cancer 2013; 49(suppl 2):S774-5
7. Gilbert MR, Dignam J, Won M, et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 2013;31(18S):1
8. Cao L, Jiao X, Zuzga DS, et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet 2004;36(8):827-35
9. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience. Neurology 2009;72(14):1217-22
10. Herrlinger U, Schafer N, Steinbach JP, et al. Bevacizumab, irinotecan and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT - non methylated glioblastoma patients: Updated results from the randomized multicenter GLARIUS Trial. Eur J Cancer 2013;49(suppl 2):S774
11. Stupp R, Hegi ME, Gorlia T, et al. Standard chemoradiotherapy ± cilengitide in newly diagnosed glioblastoma (GBM): Updated results and subgroup analyses of the international randomized phase III CENTRIC Trial (EORTC trial 26071- 22072/Canadian Brain tumor Consortium). Eur J Cancer 2013;49(suppl 2):S775.